Changes this week
Changes detected in the 7 days to Nov 20, 2026
- Minor: Monitoring Combined Effect of Balance and Strengthening Exercises on Static and Dynamic Balance in Elderly Populations Completed without a posted recruiting period
- Minor: Multiple-Session Transcranial Direct Current Stimulation (tDCS) on Behavioral, Physiological, and Electrophysiological Measures With · Autism Spectrum Disorder (ASD) Trial completed
- Minor: Perspectives of Italian Employers Regarding the Return to Work Process of Employees Who Received a Cancer Diagnosis: a Qualitative Study Primary completion pushed from Jun 2026 to Dec 2026
- Minor: Bleximenib · Acute Leukemia (cAMeLot-1) Enrollment increased: 420 → 494 participants
- Minor: ESCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents · Cancer Primary and study completion pushed from Dec 31, 2026 to Jan 31, 2027
- Minor: Sacral ESP Block and Caudal Block in Pediatric Hypospadias Surgery Primary completion pushed from Sep 1, 2026 to Dec 1, 2026
- Minor: Multi-Segmental Spinal Manual Therapy · Episodic Migraine Primary completion pushed from Nov 30, 2026 to Jan 20, 2027
- Minor: Optimizing Timing of Cesarean Delivery Consent on Labor and Delivery Primary completion pushed from Dec 2026 to Jun 2027
- Minor: Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 240 → 265 locations
- Minor: Induction Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease Trial sites expanded: 461 → 481 locations
- Minor: Symbiotic-GI-16 · PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer Trial sites expanded: 100 → 124 locations
- Minor: Upadacitinib · Alopecia Areata Trial sites expanded: 13 → 22 locations
- Minor: NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness Trial sites expanded: 4 → 7 locations
- Minor: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Trial sites expanded: 200 → 209 locations
- Minor: Intravenous Anifrolumab · Systemic Lupus Erythematosus in Pediatric Participants Trial sites expanded: 103 → 111 locations
- Minor: Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Trial sites expanded: 93 → 97 locations
- Minor: Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder Trial sites reduced: 62 → 56 locations
- Minor: Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma Trial sites expanded: 1 → 11 locations
- Minor: Pegozafermin · MASH and Fibrosis (ENLIGHTEN-Fibrosis) Trial sites expanded: 370 → 375 locations
- Minor: Maintenance Study to Investigate the Efficacy and Safety of Duvakitug · Moderately to Severely Active Crohn's Disease Trial sites expanded: 109 → 152 locations
- Minor: Rimegepant in Adults When Used · Chronic Migraine Trial sites expanded: 19 → 38 locations
- Minor: Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures Trial sites reduced: 136 → 133 locations
- Minor: Momelotinib · Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome Trial sites expanded: 0 → 3 locations
- Minor: Oral Levosimendan Trial sites expanded: 9 → 14 locations
- Minor: Symbiotic-GU-06 · PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer Trial sites expanded: 184 → 198 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates